Literature DB >> 20138495

Dietary α- and γ-tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis.

Min-Yu Chung1, Steven F Yeung, Hea Jin Park, Jeff S Volek, Richard S Bruno.   

Abstract

Oxidative stress contributes towards the development of nonalcoholic steatohepatitis (NASH). Thus, antioxidants may decrease oxidative stress and ameliorate the events contributing to NASH. We hypothesized that α- or γ-tocopherol would protect against lipopolysaccharide (LPS)-triggered NASH in an obese (ob/ob) mouse model. Five-week-old obese mice (n=18/dietary treatment) were provided 15 mg/kg each of α- and γ-tocopherol or 500 mg/kg of α- or γ-tocopherol for 5-weeks. Then, all mice were injected ip once with LPS (250 μg/kg) before being sacrificed at 0, 1.5 or 6 h. Body weight and hepatic steatosis were unaffected by tocopherols and LPS. Hepatic α- and γ-tocopherol increased (P<.05) ~9.8- and 10-fold in respective tocopherol supplemented mice and decreased in response to LPS. LPS increased serum alanine aminotransferase (ALT) by 86% at 6 h and each tocopherol decreased this response by 29-31%. By 6 h, LPS increased hepatic malondialdehyde (MDA) and tumor necrosis factor-α by 81% and 44%, respectively, which were decreased by α- or γ-tocopherol. Serum ALT was correlated (P<.05) to hepatic tumor necrosis factor-α (r=0.585) and MDA (r=0.592), suggesting that inflammation and lipid peroxidation contributed to LPS-triggered hepatic injury. α- and γ-Tocopherol similarly attenuated LPS-triggered increases in serum free fatty acid, and α-tocopherol only maintained the LPS-triggered serum triacylglycerol responses at 6 h. These findings indicate that increasing hepatic α- or γ-tocopherol protected against LPS-induced NASH by decreasing liver damage, lipid peroxidation, and inflammation without affecting body mass or hepatic steatosis. Further study is needed to define the mechanisms by which these tocopherols protected against LPS-triggered NASH.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138495     DOI: 10.1016/j.jnutbio.2009.10.006

Source DB:  PubMed          Journal:  J Nutr Biochem        ISSN: 0955-2863            Impact factor:   6.048


  22 in total

Review 1.  Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Sanja Stojsavljević; Marija Gomerčić Palčić; Lucija Virović Jukić; Lea Smirčić Duvnjak; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 2.  Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment.

Authors:  Ming-Ming Chen; Jing-Jing Cai; Yao Yu; Zhi-Gang She; Hongliang Li
Journal:  Gene Expr       Date:  2019-04-02

Review 3.  Pharmacotherapy for Nonalcoholic Fatty Liver Disease.

Authors:  Samer Gawrieh; Naga Chalasani
Journal:  Semin Liver Dis       Date:  2015-09-17       Impact factor: 6.115

Review 4.  Genetic determinants of hepatic steatosis in man.

Authors:  Amanda J Hooper; Leon A Adams; John R Burnett
Journal:  J Lipid Res       Date:  2011-01-18       Impact factor: 5.922

Review 5.  Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis.

Authors:  Yaron Ilan
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

Review 6.  Vitamin E and nonalcoholic fatty liver disease.

Authors:  Tommy Pacana; Arun J Sanyal
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2012-11       Impact factor: 4.294

Review 7.  Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition.

Authors:  Minjie Lin; Shuiping Zhao; Li Shen; Danyan Xu
Journal:  Drug Saf       Date:  2014-04       Impact factor: 5.606

8.  Vitamin E does not prevent Western diet-induced NASH progression and increases metabolic flux dysregulation in mice.

Authors:  Clinton M Hasenour; Arion J Kennedy; Tomasz Bednarski; Irina A Trenary; Brandon J Eudy; Robin P da Silva; Kelli L Boyd; Jamey D Young
Journal:  J Lipid Res       Date:  2020-02-21       Impact factor: 5.922

9.  The natural history of cirrhosis from parenteral nutrition-associated liver disease after resolution of cholestasis with parenteral fish oil therapy.

Authors:  Prathima Nandivada; Melissa I Chang; Alexis K Potemkin; Sarah J Carlson; Eileen Cowan; Alison A Oʼloughlin; Paul D Mitchell; Kathleen M Gura; Mark Puder
Journal:  Ann Surg       Date:  2015-01       Impact factor: 12.969

10.  Focus on therapeutic strategies of nonalcoholic Fatty liver disease.

Authors:  Marilena Durazzo; Paola Belci; Alessandro Collo; Enrica Grisoglio; Simona Bo
Journal:  Int J Hepatol       Date:  2012-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.